| __timestamp | BioCryst Pharmaceuticals, Inc. | Evotec SE |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 17990000 |
| Thursday, January 1, 2015 | 13047000 | 25166000 |
| Friday, January 1, 2016 | 11253000 | 27013000 |
| Sunday, January 1, 2017 | 13933000 | 42383000 |
| Monday, January 1, 2018 | 29514000 | 57012000 |
| Tuesday, January 1, 2019 | 37121000 | 66546000 |
| Wednesday, January 1, 2020 | 67929000 | 77238000 |
| Friday, January 1, 2021 | 118818000 | 105445000 |
| Saturday, January 1, 2022 | 159371000 | 156190000 |
| Sunday, January 1, 2023 | 213894000 | 169610000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial for success. BioCryst Pharmaceuticals, Inc. and Evotec SE, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 280%, reflecting a strategic expansion and investment in growth. In contrast, Evotec's expenses increased by approximately 840%, indicating a robust scaling of operations.
BioCryst's expenses grew steadily, with a notable jump in 2021, reaching 118 million USD, a 75% increase from the previous year. Meanwhile, Evotec's expenses peaked in 2023 at 170 million USD, marking a 9% rise from 2022. These trends highlight the companies' differing approaches to managing operational costs while pursuing innovation and market expansion.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: argenx SE vs Evotec SE
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Evotec SE
Ascendis Pharma A/S or Evotec SE: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Mesoblast Limited vs Evotec SE: SG&A Expense Trends